"One in three" lack drug access in India

17 December 2007

One in three people in India lack access to medicines for economic reasons, despite the fact that the country is the fourth largest location for drug manufacturing in the world, according to the National Campaign Committee on Drug Policy. Amit Sen Gupta, the group's secretary, told a conference in New Delhi that the only way to tackle the problem would be for the government to centralize the management of public sector drugmakers, forcing them to concentrate on diseases which mostly affect the poor.

Together with the Federation of Medical Representatives Associations of India, Jan Swasthya Abhiyan and the all-India Drugs Action Network (AIDAN), the NCCDP called on the Indian government to include a manufacturing strategy as part of a new pharmaceutical policy. The non-governmental organizations also agreed that responsibility for the policy should be shared between the Ministries of Health and Chemicals, according to a report by the locally-based Pharmabiz.com.

1948 pharmacy rules to be amended

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight